Dr. Rodney Nash, Ph.D., Co-Founder & President/CEO, Jeevan Biosciences, Inc., and advisor for Quorum X Diagnostics brings with him extensive training in human development and disease, particularly in identifying biomarkers using embryonic models. His research efforts have resulted in the identification of unique biomarkers associated with cancer stem cells relating to different types of cancer such as brain, breast, and skin cancer.

While earning his graduate degree at the University of Georgia, he trained at BresaGen (Athens, GA) which has become highly regarded for being one of the first biotechnology companies to isolate and develop their own line of human embryonic stem cells. This training allowed Dr. Nash to direct his research efforts towards identifying and publishing unique glycans associated with pluripotency. Dr. Nash was trained in high-throughput analysis during his Post-Doctorate research efforts where his focus became neurodegenerative disease and toxicology. He studied disease conditions similar to those seen in brain cancer, alcohol, and drug addiction, as well as HIV/NeuroAIDS.

In addition to serving as an advisor for Quorum X Diagnostics, Dr. Nash is the President/CEO of Jeevan Biosciences, the company he founded, as well as CSO and Product Manager for Omni International. Dr. Nash is a part-time Biology professor & guest lecturer at Georgia State University and serves as a board member for Children’s Health Care of Atlanta-Scottish Rite and sits on the Committee for Family Experience. He also works as a consultant for two other biotech/life science companies and is a Technology Grant Reviewer (Office of Technology Transfer) at Emory University.

Dr. Nash received his B.S. in Molecular Biology & Chemistry and his M.S. in Molecular Genetics & Biochemistry from Georgia State University. He earned his Ph.D. in Animal Science from the University of Georgia. Dr. Nash has published more than 20 peer-reviewed papers and holds four patents. His business acumen along with his extensive research and training in molecular genetics and human development and disease makes him a valuable asset as an advisor for QXD.